(MENAFN- IMARC Group) According to IMARC Group’s latest report, titled “Oncology Molecular Diagnostics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026,” the global oncology molecular diagnostics market exhibited strong growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of 12.6% during 2021-2026.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Oncology molecular diagnostics are used to detect the presence of cancerous cells by analyzing the biological molecules. Various tests are performed on blood, saliva, and tumor tissue samples to identify and measure specific genetic sequences in DNA, RNA, and cell proteins. Oncology molecular diagnostics assist in early cancer detection and provide required information pertaining to personalized cancer treatment. They are often used in clinical and point-of-care (POC) testing, along with identifying pathogens and infectious diseases present in the donated blood samples in blood banks.
Market Trends
The increasing occurrence of oncological disorders due to unhealthy consumer lifestyles, rising geriatric population, and the growing tobacco consumption, is primarily driving the demand for oncology molecular diagnostics. In line with this, the growing need for early and accurate diagnosis, coupled with several advancements in next-generation sequencing (NGS) techniques, further contributes to the market growth. Moreover, the rising prevalence of viral and bacterial infections, along with the expanding number of blood donation campaigns, is further bolstering the demand for oncology molecular diagnostics.
List of Key Companies Covered in this Market Report:
Agilent Technologies Inc.
Abbott Laboratories
Bayer AG
BD (Becton, Dickinson and Company)
Cepheid Inc. (Danaher Corporation)
Hoffmann-La Roche AG
Hologic Inc.
Qiagen N.V.
Siemens Healthcare and Sysmex Corporation.
The report has segmented the market on the basis of cancer type, product, technology, end-user and geography.
Breakup by Cancer Type:
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Others
Breakup by Product:
Instruments
Reagents
Others
Breakup by Technology:
Polymerase Chain Reaction (PCR)
In Situ Hybridization
Chips and Microarrays
Isothermal Nucleic Acid Amplification Technology (INAAT)
Mass Spectrometry
DNA and NGS Sequencing
Transcription Mediated Amplification (TMA)
Others
Breakup by End-User:
Hospitals and Clinics
Reference Laboratories
Others
Breakup by Geography:
North America (U.S. & Canada)
Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
Latin America (Brazil, Mexico)
Middle East & Africa
Key highlights of the report:
Market Performance (2015-2020)
Market Outlook (2021- 2026)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
SWOT Analysis
Value Chain
Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
MENAFN04082021004122009559ID1102565730
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.